MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies reports record attendance at ICCU 2015 and at the associated post-graduate course on endomicroscopy

Transparency directive : regulatory news

15/04/2015 18:00

PRESS RELEASE

    MAUNA KEA TECHNOLOGIES REPORTS RECORD ATTENDANCE AT ICCU 2015 AND AT THE
                ASSOCIATED POST-GRADUATE COURSE ON ENDOMICROSCOPY

* 300 physicians and surgeons gathered in Lisbon at the International Conference
  of Cellvizio Users to discuss advancements and benefits of endomicroscopy in
                    multiple medical and surgical indications

  * First post-graduate course organized and chaired by Pr. Satish Singh from
                               Boston University

PARIS, France - April 15, 2015 - Mauna Kea Technologies (Euronext: MKEA,
FR0010609263), inventor of Cellvizio(r), the multidisciplinary confocal laser
endomicroscopy platform, announced today the success record attendance of the
7th edition of the International Conference of Cellvizio Users (ICCU 2015).
About 300 physicians and surgeons gathered in Lisbon, Portugal, from April 10 to
April 12 for two days of intense training and discussions on the wide number of
clinical and pre-clinical indications of Confocal Laser Endomicroscopy in
research, medicine and surgery. Earlier this year, an 18 member scientific
committee, chaired by Pr. Jean-Paul Galmiche from Nantes University Hospital,
selected best abstracts among the large quantity of work submitted, to create a
dense program with multiple plenary and breakout sessions.

"This 7th edition of ICCU, the largest and most multi-disciplinary one to date,
reflected the growing importance of confocal laser endomicroscopy in many fields
of medicine and surgery" said Dr Gregory Y. Lauwers, Vice Chairman of Pathology
and Director of Gastrointestinal Pathology at the Massachusetts General Hospital
in Boston and co-Chairman of ICCU 2015, "The fast growing collaboration between
pathologists and clinical users of endomicroscopy worldwide is patent and key to
drive adoption of optical biopsy, through training and joint patient management
decisions."

For the first-time, a post-graduate course was held in parallel of ICCU and
could barely accommodate the number of attendees who listened to leaders in
their field discuss the clinical use of endomicroscopy for a wide range of
gastroenterological applications: characterization of pancreatic cysts and
biliary strictures, management of patients with Inflammatory Bowel Disease,
Barrett's Esophagus and early squamous cell carcinoma to name a few.

"ICCU 2015 was, once again, a clear expression of the growing role of
endomicroscopy in multiple applications, enabling physicians and now surgeons
from many specialties to have a more efficient workflow for the benefit of the
patient", concludes Sacha Loiseau, CEO and founder of Mauna Kea Technologies.

The full scientific program of ICCU 2015 can be downloaded here

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard endoscopy procedures. The company's flagship product,
Cellvizio(r), a probe needle based Confocal Laser Endomicroscopy (pCLE/nCLE)
system, provides physicians and researchers with high-resolution cellular
imaging of internal tissues. Large-scale, international, multi- center clinical
trials have demonstrated Cellvizio's ability to help physicians to more
accurately detect early forms of diseases and make immediate treatment
decisions. Designed to help physicians in their diagnoses, provide patients with
better treatment and reduce hospital costs, the Cellvizio system can be used
with virtually any endoscope. Cellvizio has 510(k) clearance from the United
States Food and Drug Administration and CE Marking in the European Union for use
in the gastrointestinal tract and the urinary and respiratory systems, for
endoscopic exploration of the biliary and pancreatic ducts and for fine-needle
aspiration procedures. Cellvizio has also obtained SFDA regulatory approval in
China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies             France & Europe
Eric Cohen                         NewCap - Investor Relations &
Vice-President Finance             Financial Communication
Tel. : +33 (0)1 70 08 09 70        Florent Alba / Pierre Laurent
investor-vpf@maunakeatech.com      Tel. : +33 (0)1 44 71 94 94
                                   maunakea@newcap.fr

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies reports record attendance at ICCU 2015 and at the associated post-graduate course on endomicroscopy

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories